Covid-19 roundup: Val­ne­va de­fends vac­cine in wake of un­flat­ter­ing boost­er study; Mer­ck goes af­ter Pfiz­er’s new an­tivi­ral — re­port

Falling way be­hind the fron­trun­ners in de­liv­er­ing a Covid-19 vac­cine, French biotech Val­ne­va has placed high hopes on boost­ers.

Which may be why it is re­act­ing strong­ly to a study sug­gest­ing that its can­di­date, VLA2001, was the on­ly one out of sev­en that didn’t work well as a boost­er for vol­un­teers who had dos­es of the Pfiz­er/BioN­Tech mR­NA shot.

The com­pa­ny is try­ing to fire back Mon­day morn­ing, days af­ter re­sults from the COV-Boost study were pub­lished in The Lancet.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER